Previous immune‐related therapeutic approaches for stroke focus on inhibiting pro‐inflammatory cytokines, such as IL‐6 or TNF‐α, which are involved in the inflammatory response and neuroinflammation post‐stroke. The gene discussed is TNF; the disease is stroke disorder.